The Food and Drug Administration Aug. 12 approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection.
Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a pill taken daily in combination with other antiretroviral drugs.
The drug was developed by ViiV Healthcare, a global specialist HIV company established in November 2009 by GlaxoSmithKline and Pfizer. Shionogi joined as a 10 percent shareholder in October 2012.
Broad Patient Population.
Tivicay is approved for use in a broad population of HIV-infected patients, the agency said. It can be used ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.